Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>TGFβR2</i> aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma

19 Mar 2009

Abstract excerpt

Multiple myeloma (MM) is an incurable hematological malignancy. Different studies demonstrated the occurrence of genetic and epigenetic alterations in MM. The aberrant methylation is one of the most frequent epigenetic alterations in human genome. This study evaluated the aberrant methylation status of 20 genes in 51 MM samples by quantitative methylation-specific PCR (QMSP) and compared the methylation profile...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Multiple Myeloma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19548309
DOI: 10.1002/ijc.24431

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>TGFβR2</i> aberrant methylation is a potential prognostic marker and therapeutic target in multiple myelomaPMID 19548309Read ↗

The Role of Epigenetics in the Development and Progression of Multiple MyelomaSemantic proximity Read ↗

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity Read ↗

Epigenetic Aberrations in Multiple MyelomaSemantic proximity Read ↗

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.Semantic proximity Read ↗

Detecting methylation patterns of <i>p16</i>, <i>MGMT</i>, <i>DAPK</i> and <i>E‐cadherin</i> genes in multiple myeloma patientsSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myelomaSemantic proximity Read ↗

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSemantic proximity Read ↗

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsSemantic proximity Read ↗

Therapeutic Potential of PRMT1 as a Critical Survival Dependency Target in Multiple MyelomaSemantic proximity Read ↗

The biological significance of histone modifiers in multiple myeloma: clinical applicationsSemantic proximity Read ↗

DNA hydroxymethylation reveals transcription regulation networks and prognostic signatures in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.